Bavarian Nordic Acquires Emergent BioSolutions’ Travel Health Business for up to $380 Million
Bavarian Nordic has acquired Emergent BioSolutions’ travel health business for up to $380 million. Upon closing of the transaction, Bavarian Nordic will pay Emergent $270 million in upfront cash consideration. Bavarian Nordic will also pay Emergent up to $30 million in sales-based milestones associated with commercial products and up to $80 million in development-based milestones associated with the CHIKV VLP program. Bavarian Nordic will acquire Emergent’s manufacturing site in Bern, Switzerland, and development facilities in San Diego, California. Approximately 280 Emergent employees are expected to join Bavarian Nordic as part of the transaction that is expected to close in... Read More »
ReLive Biotechnologies Acquires Co.Don AG
China-based ReLive Biotechnologies, Ltd. has acquired Germany-based Co.Don AG. Terms of the deal were not disclosed. ReLive Biotechnologies is taking over the global patent rights of Spherox and Chondrosphere. Spherox is one of two authorized cell therapies for the regenerative treatment of articular cartilage defects globally. Co.Don AG is a biopharmaceutical company that develops, produces and markets cell-based pharmaceutical products for joint preservation and the regenerative treatment of articular cartilage defects worldwide. According to data captured in the LevinPro HC database, this acquisition represents the 16th Biotechnology deal of 2023. There were 141 Biotechnology... Read More »
Sun Pharmaceutical Industries Acquires Concert Pharmaceuticals in $576 Million Deal
Sun Pharmaceutical Industries Limited has acquired Concert Pharmaceuticals, Inc. for $576 million. Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment of $8 per share of common stock in cash. Concert stockholders will also receive a non-tradeable contingent value right (CVR) entitling holders to receive up to an additional $3.50 per share of common stock in cash, payable upon Concert’s candidate deuruxolitinib achieving certain net sales milestones within specified periods, subject to the terms and conditions contained in a contingent value rights agreement detailing the terms of the CVRs. Concert is a late-stage clinical... Read More »
Agilent Technologies Acquires Avida Biomed
Agilent Technologies Inc. has acquired Avida Biomed. The acquisition augments Agilent’s strategy to expand into the high-growth clinical research and diagnostics markets. Terms of the deal were not disclosed. Agilent provides bio-analytical solutions and services to the life sciences, diagnostics and genomics, chemical analysis, communications and electronics industries worldwide. Its global headquarters is in Santa Clara, California. Agilent was established in 1999 as a spin-off from Hewlett-Packard. Fremont, California-based Avida Biomed is an early-stage life sciences company that develops target enrichment workflows with capabilities for clinical researchers utilizing next-generation... Read More »
Blacksmith Medicines Merges With Forge Therapeutics
Blacksmith Medicines merged with Forge Therapeutics in a combination of two San Diego-based biotechnology companies. The Blacksmith platform has been validated through multiple pharmaceutical partnerships, including deals with Roche, Eli Lilly and Company and Basilea Pharmaceutica, which have the potential to earn more than $800 million in milestone payments plus royalties. The company has earned non-dilutive federal awards of up to $25.3 million to fully fund its infectious disease programs to the end of Phase 1. Blacksmith investors include Evotec A.G., MagnaSci Ventures, MP Healthcare Partners, Alexandria Venture Investments and Eli Lilly. Blacksmith Medicines works to discover... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
